AstraZeneca today announced it has decided to stop the CRESTOR JUPITER clinical study early based on a recommendation from an Independent Data Monitoring Board and the JUPITER Steering Committee, whi
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
New Phase III data showed that in patients with multiple lipid problems, Abbott's investigational TriLipix(TM) (ABT-335) combined with AstraZeneca's CRESTOR(R) (rosuvastatin calcium) led to greater
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
AstraZeneca and Abbott announced today that they have entered into an agreement for Abbott to promote AstraZeneca's CRESTOR® (rosuvastatin calcium), a medication used along with diet to reduce high
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
New data from the JUPITER study demonstrated that CRESTOR® (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardia
read more » Discuss Add this link to...Bury Add to:
| Bookmarks